A Phase 2 interventional study of GWP42003-P and Placebo in Autism Spectrum Disorder, sponsored by Jazz Pharmaceuticals. Completed at 23 sites in 6 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 773 studies in Autism Spectrum Disorder with a site in United States — 165 open to participants now, 204 under way, 9 of them phase 3. Autism Spectrum Disorder · United States.
Among the 773 studies in Autism Spectrum Disorder with a site in United States, this one is the 163rd largest by enrollment of the 658 interventional ones that give a count, is one of 64 that started in 2021, is one of 101 in phase 2, and was the 465th registered.
1,728 studies on the registry are indexed under Autism Spectrum Disorder; 500 are open to participants now.
Browse Autism Spectrum Disorder studies →165 of the 773 studies in Autism Spectrum Disorder with a site in United States are open now. Recruiting first, the newest first:
New York State Institute for Basic Research · Sites in United States
Ages 5–12
Massachusetts General Hospital · Sites in United States
Ages 12–17
Schweitzer Engineering Laboratories · Sites in United States
Ages 24 mo–60 mo · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 12–18
Bristol-Myers Squibb · Sites in United States, Australia, Canada and 1 more country
Ages 5–17
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 349 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 294 (84%) stop at 75 or younger; 298 take children under 18; 92 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
773 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 117 · Phase 3 33 · Phase 4 16
First in 2004; this study’s year is marked. 64 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 103 is above the median of 52 across 1,370 interventional studies indexed under Autism Spectrum Disorder.
Median enrollment 50 across the 658 interventional studies, 132 across the 114 observational. Of the 522 that completed or were terminated, 174 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
89 of 773 have an industry lead sponsor. The 10 most frequent:
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
Jazz Pharmaceuticals has 3 studies filed under Autism Spectrum Disorder — fewer than ten, so there is no comparison to draw.
67 of the studies in Autism Spectrum Disorder with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06706674Phase 3Intra-Cellular Therapies, Inc.Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients | 2027-06-21 |
| NCT06690398Phase 3Intra-Cellular Therapies, Inc.Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients | 2027-06-21 |
| NCT07670000Natalia PoluektovaMental And Speech Developmental Delay Autism Spectrum-Type Behavioral Disorder | 2026-11 |
| NCT04242355Yale UniversityTranscranial Magnetic Stimulation on Neural and Behavioral Facets of Social Cognition in Autism Spectrum Disorder | 2026-12 |
| NCT06059352Loma Linda UniversitySleep and Central Auditory Processing Disorder in Autism Spectrum Disorder | 2026-12 |
Add all 67 to your calendar (.ics) → With an account.
Among the 773 studies in Autism Spectrum Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will be conducted to evaluate the efficacy of GWP42003-P, compared with placebo, in reducing symptom severity in children with Autism Spectrum Disorder (ASD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be stratified based on their age (6 to 11 years old, 12 to 17 years old), use of antipsychotics (on versus off), and region (North America versus Rest of the World) and will be randomized to receive 5 milligrams per kilogram per day (mg/kg/day) GWP42003-P for 1 week and then 10 mg/kg/day GWP42003-P for 11 weeks.
Drug: GWP42003-P
Participants will be stratified based on their age (6 to 11 years old, 12 to 17 years old), use of antipsychotics (on versus off), and region (North America versus Rest of the World) and will be randomized to receive matching placebo for 12 weeks.
Drug: Placebo
GWP42003-P oral solution (100 milligrams per milliliter \[mg/mL\] cannabidiol \[CBD\] in sesame oil with anhydrous ethanol, ethanol \[10% v/v\] sweetener \[sucralose\], and strawberry flavoring), administered twice a day (morning and evening)
Also known as: Epidiolex®, cannabidiol, CBD-OS
Oral placebo to match GWP42003-P oral solution containing sesame oil with anhydrous ethanol, sweetener (sucralose), strawberry flavoring, and beta carotene, administered twice a day (morning and evening)
Change From Baseline in Aberrant Behavior Checklist (ABC) Subscale Total Scores
The caregiver-assessed ABC was designed to assess the presence and severity of various problem behaviors commonly observed in individuals diagnosed with intellectual and developmental disability. The checklist contains 5 subscales: Irritability (15 items); Social Withdrawal (16 items); Stereotypic Behavior (7 items); Hyperactivity/Noncompliance (16 items); and Inappropriate Speech (4 items). Each item is scored as 0 (never a problem), 1 (slight problem), 2 (moderately serious problem), or 3 (severe problem). The total score of all items for each subscale range from 0-45 (irritability), 0-48 (social withdrawal and hyperactivity/noncompliance), 0-21 (stereotypic behavior), and 0-12 (inappropriate speech) where higher scores indicate worse clinical outcome. The change from baseline to Week 4, Week 8, and Week 12 is reported with lower scores indicating better clinical outcome.
Time frame: Baseline up to Week 12
Change From Baseline in Vineland Adaptive Behavior Scales-3 (VABS-3) Scores
The VABS-3 scales assess what a person does, rather than what he or she can do. The Vineland-3 assesses adaptive behavior in 3 domains: Communication, Daily Living Skills, and Socialization. Each domain is comprised of 3 subdomains: receptive expression and written (communication); personal, domestic and community (daily living skills); Interpersonal relationships, play and leisure and copying skills (socialization). The adaptive behavior composite score is calculated as arithmetic mean of all 3 domain scores. The total score range is 20 to 140, where low scores indicate low (worst) clinical outcome and high scores indicate high (best) clinical outcome. The change from baseline in VABS-3 is being reported with positive values indicating a positive improvement in adaptive behavior.
Time frame: Baseline up to Week 12
Number of Patients Per Clinical Global Impression Improvement (CGI-I) Category
The CGI-I is a 7-point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. The clinician is asked: Compared to the patient's condition at admission to the project, how much has the patient changed? This is rated as: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse. Higher scores indicate worse clinical outcome. The number of patients in each CGI-I category is reported.
Time frame: Day 85
Change From Baseline in Clinical Global Impression Severity (CGI-S) Scores
The CGI-S is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's experience with patients who have the same diagnosis. The clinician is asked: Considering your total clinical experience with this particular population, how ill is the patient at this time? This is rated as: 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; or 7 = extremely ill. Higher scores indicate worse outcome. The change from baseline in CGI-S scores is reported and lower mean scores indicate better outcome.
Time frame: Baseline up to Week 12
Number of Participants Reporting Treatment-emergent Adverse Events
A TEAE is one that started, or worsened in severity or seriousness, following the first dose of IMP. AEs were coded according to the Medical Dictionary for Regulatory Activities v24.0 dictionary.
Time frame: Baseline up to Week 12
Mean Change From Baseline in Hematology Clinical Laboratory Levels
Time frame: Baseline up to Week 9 (end of taper/withdrawal)
Mean Percentage Change From Baseline in Hematology Clinical Laboratory Levels
Time frame: Baseline up to Week 9 (end of taper/withdrawal)
Mean Change From Baseline in Hemoglobin Levels
Time frame: Week 9 (end of taper/withdrawal)
Mean Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin Levels
Time frame: Week 9 (end of taper/withdrawal)
Mean Change From Baseline in Erythrocyte Mean Corpuscular Volume Levels
Time frame: Week 9 (end of taper/withdrawal)
Number of Patients With Clinically Significant Vital Sign Values
Time frame: Post-baseline up to 12 weeks
Number of Patients With Clinically Significant Physical Examination Procedure Findings
Number of patients with abnormal physical exam findings are reported.
Time frame: Baseline up to Day 85 post-baseline
Number of Patients With Clinically Significant 12-lead Electrocardiogram Findings
Time frame: Baseline up to Day 85 post-baseline
Number of Participants Reporting Suicidal Ideation or Behavior Using the Columbia-Suicide Severity Rating Scale (C-SSRS)
C-SSRS rating scale results since last visit is reported. The presence/absence of any suicidal ideation or behavior is scored based on yes/no responses. The overall number of participants reporting suicidal ideation or behavior is being reported.
Time frame: Baseline up to Day 92
A total of 191 patients were screened for this study. Of those 191 patients, 103 patients met all inclusion criteria and no exclusion criteria were enrolled in the study and randomized to treatment at 24 centers in the United States, Canada, Spain, United Kingdom, and Australia.
| Milestone | GWP42003-P | Placebo |
|---|---|---|
| Started | 49 | 54 |
| Completed | 36 | 41 |
| Not completed | 13 | 13 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Protocol violation | 1 | 3 |
| Withdrew: Lost to follow-up | 4 | 3 |
| Withdrew: Withdrawal by subject | 5 | 5 |
The caregiver-assessed ABC was designed to assess the presence and severity of various problem behaviors commonly observed in individuals diagnosed with intellectual and developmental disability. The checklist contains 5 subscales: Irritability (15 items); Social Withdrawal (16 items); Stereotypic Behavior (7 items); Hyperactivity/Noncompliance (16 items); and Inappropriate Speech (4 items). Each item is scored as 0 (never a problem), 1 (slight problem), 2 (moderately serious problem), or 3 (severe problem). The total score of all items for each subscale range from 0-45 (irritability), 0-48 (social withdrawal and hyperactivity/noncompliance), 0-21 (stereotypic behavior), and 0-12 (inappropriate speech) where higher scores indicate worse clinical outcome. The change from baseline to Week 4, Week 8, and Week 12 is reported with lower scores indicating better clinical outcome.
| score on a scale | GWP42003-P | Placebo |
|---|---|---|
| ABC-Irritability, Week 4 | -6.35 ± 7.98 | -5.41 ± 7.16 |
| ABC-Irritability, Week 8 | -6.67 ± 8.63 | -8.05 ± 9.12 |
| ABC-Irritability, Week 12 | -6.97 ± 9.68 | -8.57 ± 10.10 |
| ABC-Social Withdrawal, Week 4 | -2.53 ± 5.61 | -2.92 ± 5.24 |
| ABC-Social Withdrawal, Week 8 | -3.81 ± 6.76 | -4.74 ± 6.25 |
| ABC-Social Withdrawal, Week 12 | -3.74 ± 6.21 | -4.51 ± 5.95 |
| ABC-Stereotypic Behavior, Week 4 | -2.10 ± 4.24 | -1.39 ± 3.24 |
| ABC-Stereotypic Behavior, Week 8 | -1.92 ± 3.99 | -1.98 ± 4.05 |
| ABC-Stereotypic Behavior, Week 12 | -1.88 ± 3.63 | -2.31 ± 4.03 |
| ABC-Hyperactivity/Noncompliance, Week 4 | -5.73 ± 8.08 | -4.55 ± 8.15 |
| ABC-Hyperactivity/Noncompliance, Week 8 | -6.39 ± 9.15 | -7.42 ± 9.06 |
| ABC-Hyperactivity/Noncompliance, Week 12 | -6.74 ± 10.62 | -8.77 ± 9.94 |
| ABC-Inappropriate Speech, Week 4 | -2.13 ± 2.88 | -0.88 ± 2.07 |
| ABC-Inappropriate Speech, Week 8 | -1.58 ± 2.74 | -1.44 ± 2.73 |
| ABC-Inappropriate Speech, Week 12 | -1.94 ± 2.93 | -1.51 ± 2.97 |
The VABS-3 scales assess what a person does, rather than what he or she can do. The Vineland-3 assesses adaptive behavior in 3 domains: Communication, Daily Living Skills, and Socialization. Each domain is comprised of 3 subdomains: receptive expression and written (communication); personal, domestic and community (daily living skills); Interpersonal relationships, play and leisure and copying skills (socialization). The adaptive behavior composite score is calculated as arithmetic mean of all 3 domain scores. The total score range is 20 to 140, where low scores indicate low (worst) clinical outcome and high scores indicate high (best) clinical outcome. The change from baseline in VABS-3 is being reported with positive values indicating a positive improvement in adaptive behavior.
| score on a scale | GWP42003-P | Placebo |
|---|---|---|
| Week 4 | 2.97 ± 6.70 | 0.99 ± 9.29 |
| Week 8 | 3.69 ± 10.82 | 3.54 ± 8.83 |
| Week 12 | 4.85 ± 8.83 | 5.55 ± 10.42 |
The CGI-I is a 7-point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. The clinician is asked: Compared to the patient's condition at admission to the project, how much has the patient changed? This is rated as: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse. Higher scores indicate worse clinical outcome. The number of patients in each CGI-I category is reported.
| Participants | GWP42003-P | Placebo |
|---|---|---|
| Minimally improved | 13 | 14 |
| Much improved | 12 | 11 |
| No change | 9 | 11 |
| Much worse | 0 | 1 |
| Very much improved | 0 | 1 |
| Minimally worse | 0 | 0 |
| Very much worse | 0 | 0 |
The CGI-S is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's experience with patients who have the same diagnosis. The clinician is asked: Considering your total clinical experience with this particular population, how ill is the patient at this time? This is rated as: 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; or 7 = extremely ill. Higher scores indicate worse outcome. The change from baseline in CGI-S scores is reported and lower mean scores indicate better outcome.
| score on a scale | GWP42003-P | Placebo |
|---|---|---|
| Week 4 | -0.33 ± 0.61 | -0.31 ± 0.69 |
| Week 8 | -0.50 ± 0.68 | -0.48 ± 0.92 |
| Week 12 | -0.55 ± 0.85 | -0.63 ± 1.10 |
A TEAE is one that started, or worsened in severity or seriousness, following the first dose of IMP. AEs were coded according to the Medical Dictionary for Regulatory Activities v24.0 dictionary.
| Participants | GWP42003-P | Placebo |
|---|---|---|
| TEAE | 27 | 24 |
| Non-TEAE | 25 | 32 |
| Treatment-related TEAE | 6 | 10 |
| Serious TEAE | 2 | 1 |
| Serious Treatment-related TEAE | 0 | 0 |
| TEAE leading to study intervention withdrawal | 2 | 1 |
| Treatment-related TEAE leading to drug withdrawal | 1 | 1 |
| TEAE leading to withdrawal | 2 | 2 |
| TEAE leading to death | 0 | 0 |
| 10^9 cells/L | GWP42003-P | Placebo |
|---|---|---|
| Week 9: Basophils | -0.01 ± 0.03 | 0 ± 0.03 |
| Week 9: Eosinophils | -0.09 ± 0.311 | 0 ± 0.40 |
| Week 9: Lymphocytes | 0.04 ± 0.70 | -0.20 ± 0.68 |
| Week 9: Monocytes | -0.01 ± 0.15 | -0.01 ± 0.19 |
| Week 9: Neutrophils | 0.04 ± 1.80 | -0.01 ± 1.26 |
| Week 9: Platelets | -9.43 ± 34.50 | 8.43 ± 52.13 |
| Week 9: Leukocytes | -0.02 ± 1.87 | -0.23 ± 1.79 |
| percentage change from baseline | GWP42003-P | Placebo |
|---|---|---|
| Week 9: Basophils/Leukocytes | -0.07 ± 0.45 | -0.03 ± 0.42 |
| Week 9: Eosinophils/Leukocytes | -1.33 ± 5.37 | 0.22 ± 4.88 |
| Week 9: Hematocrit | -0.02 ± 2.19 | 0.43 ± 2.30 |
| Week 9: Lymphocytes/Leukocytes | 1.05 ± 11.25 | -2.32 ± 8.26 |
| Week 9: Monocytes/Leukocytes | -0.16 ± 2.04 | 0.05 ± 1.86 |
| Week 9: Neutrophils/Leukocytes | 0.49 ± 12.29 | 2.08 ± 8.89 |
| g/dL | GWP42003-P | Placebo |
|---|---|---|
| Mean Change From Baseline in Hemoglobin Levels | -0.06 ± 0.55 | 0.08 ± 0.65 |
| pg/cell | GWP42003-P | Placebo |
|---|---|---|
| Mean Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin Levels | 0.13 ± 0.67 | -0.03 ± 0.72 |
| fL | GWP42003-P | Placebo |
|---|---|---|
| Mean Change From Baseline in Erythrocyte Mean Corpuscular Volume Levels | 0.52 ± 2.32 | 0.03 ± 2.39 |
| Participants | GWP42003-P | Placebo |
|---|---|---|
| Increase in weight from baseline >7% | 7 | 13 |
| Decrease in weight from baseline >7% | 2 | 2 |
| Body temperature <36 degrees Celsius | 4 | 6 |
| Body temperature >38 degrees Celsius | 1 | 0 |
| Pulse rate <60 beats/min | 1 | 3 |
| Pulse rate >100 beats/min | 7 | 4 |
| Respiratory rate <12 breaths/min | 0 | 0 |
| Respiratory rate >20 breaths/min | 13 | 17 |
| Systolic blood pressure <90 mmhg | 5 | 3 |
| Systolic blood pressure >160 mmhg | 0 | 0 |
| Diastolic blood pressure <50 mmhg | 3 | 2 |
| Diastolic blood pressure >120 mmhg | 0 | 0 |
Number of patients with abnormal physical exam findings are reported.
| Participants | GWP42003-P | Placebo |
|---|---|---|
| Abdomen | 2 | 0 |
| Cardiovascular | 0 | 0 |
| Chest/lungs | 0 | 0 |
| Dermatological | 3 | 3 |
| Endocrine system | 0 | 0 |
| Gastrointestinal | 0 | 0 |
| General appearance | 0 | 2 |
| HEENT | 0 | 1 |
| Lymphatic | 0 | 0 |
| Musculoskeletal/Extremities | 0 | 1 |
| Neurological | 2 | 0 |
| Other | 0 | 0 |
| Genitourinary/Reproductive | 0 | 0 |
| Participants | GWP42003-P | Placebo |
|---|---|---|
| QTcB >450 msec | 7 | 4 |
| QTcB >480 msec | 2 | 0 |
| QTcB >500 msec | 1 | 0 |
C-SSRS rating scale results since last visit is reported. The presence/absence of any suicidal ideation or behavior is scored based on yes/no responses. The overall number of participants reporting suicidal ideation or behavior is being reported.
| Participants | GWP42003-P | Placebo |
|---|---|---|
| Suicidal ideation | 4 | 3 |
| Wish to be dead | 3 | 3 |
| Non-specific active suicidal thoughts | 2 | 1 |
| Active suicidal ideation, no intent to act | 1 | 0 |
| Active suicidal ideation, some intent to act | 0 | 0 |
| Active suicidal ideation, specific plan/intent | 0 | 0 |
| Suicidal behavior | 3 | 6 |
| Actual attempt | 0 | 1 |
| Interrupted attempt | 0 | 1 |
| Aborted attempt | 0 | 0 |
| Preparatory acts or behavior | 0 | 1 |
| Suicidal behavior item | 0 | 1 |
| Self-injurious behavior without suicidal intent | 3 | 5 |
| Completed suicide | 0 | 0 |
Collected over Adverse event data were collected from baseline up to 14 days after last dose, up to approximately 12 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GWP42003-P | 0/49 (0%) | 2/49 (4.1%) | 14/49 (28.6%) |
| Placebo | 0/54 (0%) | 1/54 (1.9%) | 20/54 (37%) |
| Event | GWP42003-P | Placebo |
|---|---|---|
| Suicidal ideationPsychiatric disorders | 1/49 | 0/54 |
| COVID-19Infections and infestations | 1/49 | 1/54 |
| Event | GWP42003-P | Placebo |
|---|---|---|
| VomitingGastrointestinal disorders | 7/49 | 4/54 |
| PyrexiaGeneral disorders | 0/49 | 5/54 |
| IrritabilityPsychiatric disorders | 0/49 | 5/54 |
| NasopharyngitisInfections and infestations | 4/49 | 0/54 |
| HeadacheNervous system disorders | 3/49 | 4/54 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/49 | 0/54 |
| FatigueGeneral disorders | 0/49 | 3/54 |
| Upper respiratory tract infectionInfections and infestations | 0/49 | 3/54 |
Demographic and baseline characteristics were assessed in the Safety Analysis Set.
| Age, Categorical(Participants) | GWP42003-P | Placebo | Total |
|---|---|---|---|
| <=18 years | 49 | 54 | 103 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | GWP42003-P | Placebo | Total |
|---|---|---|---|
| Mean | 11.1 ± 3.02 | 10.8 ± 3.01 | 10.9 ± 3 |
| Sex: Female, Male(Participants) | GWP42003-P | Placebo | Total |
|---|---|---|---|
| Female | 13 | 7 | 20 |
| Male | 36 | 47 | 83 |
| Race/Ethnicity, Customized(Participants) | GWP42003-P | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 3 |
| Asian | 1 | 2 | 3 |
| Black or African American | 5 | 2 | 7 |
| White | 32 | 42 | 74 |
| Multiple | 5 | 2 | 7 |
| Unknown | 2 | 1 | 3 |
| Not Reported | 1 | 2 | 3 |
| Other | 2 | 1 | 3 |
| WASI-II Intelligent Quotient Score(score on a scale) | GWP42003-P | Placebo | Total |
|---|---|---|---|
| Mean | 99.42 ± 18.03 | 100.89 ± 17.16 | 100.19 ± 17.49 |
| Aberrant Behavior Checklist Irritability(score on a scale) | GWP42003-P | Placebo | Total |
|---|---|---|---|
| Mean | 23.2 ± 7.36 | 22.5 ± 8.74 | 22.8 ± 8.09 |
| Aberrant Behavior Checklist Social Withdrawal(score on a scale) | GWP42003-P | Placebo | Total |
|---|---|---|---|
| Mean | 12.6 ± 8.63 | 12.7 ± 9.11 | 12.7 ± 8.85 |
| Aberrant Behavior Checklist Stereotypic Behavior(score on a scale) | GWP42003-P | Placebo | Total |
|---|---|---|---|
| Mean | 6.7 ± 5.08 | 6.7 ± 4.83 | 6.7 ± 4.92 |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2021 to primary completion in Dec 2023, 30 months.
Results were first posted in Mar 2025, 1 year 3 months after primary completion.
Of 82 phase 2 interventional studies under Autism Spectrum Disorder, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 52. This study's 30 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol